CoChat

Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs

Open access
Eschweiler, Simon, Ramírez-Suástegui, Ciro, Li, Yingcong, King, Emma, Chudley, Lindsey, Thomas, Jaya, Wood, Oliver, von Witzleben, Adrian, Jeffrey, Danielle, McCann, Katy, Simon, Hayley, Mondal, Monalisa, Wang, Alice, Dicker, Martina, Lopez-Guadamillas, Elena, Chou, Ting-Fang, Dobbs, Nicola A., Essame, Louisa, Acton, Gary, Kelly, Fiona, Halbert, Gavin, Sacco, Joseph J., Schache, Andrew Graeme, Shaw, Richard, McCaul, James Anthony, Paterson, Claire, Davies, Joseph H., Brennan, Peter A., Singh, Rabindra P., Loadman, Paul M., Wilson, William, Hackshaw, Allan, Seumois, Gregory, Okkenhaug, Klaus, Thomas, Gareth J., Jones, Terry M., Ay, Ferhat, Friberg, Greg, Kronenberg, Mitchell, Vanhaesebroeck, Bart, Vijayanand, Pandurangan, Ottensmeier, Christian H. · 2022 · Nature
Cited by 99

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Phosphoinositide 3-kinase δ (PI3Kδ) has a key role in lymphocytes, and inhibitors that target this PI3K have been approved for treatment of B cell malignancies 1–3 . Although studies in mouse models of solid tumours have demonstrated that PI3Kδ inhibitors (PI3Kδi) can induce anti-tumour immunity 4,5 , its effect on solid tumours in humans remains unclear. Here we assessed the effects of the PI3Kδi AMG319 in human patients with head and neck cancer in a neoadjuvant, double-blind, placebo-controlled randomized phase II trial (EudraCT no. 2014-004388-20). PI3Kδ inhibition decreased the number of tumour-infiltrating regulatory T (T reg ) cells and enhanced the cytotoxic potential of tumour-infiltrating T cells. At the tested doses of AMG319, immune-related adverse events (irAEs) required treatment to be discontinued in 12 out of 21 of patients treated with AMG319, suggestive of systemic effects on T reg cells. Accordingly, in mouse models, PI3Kδi decreased the number of T reg cells systemically and caused colitis. Single-cell RNA-sequencing analysis revealed a PI3Kδi-driven loss of tissue-resident colonic ST2 T reg cells, accompanied by expansion of pathogenic T helper 17 (T H 17) and type 17 CD8 + T (T C 17) cells, which probably contributed to toxicity; this points towards a specific mode of action for the emergence of irAEs. A modified treatment regimen with intermittent dosing of PI3Kδi in mouse models led to a significant decrease in tumour growth without inducing pathogenic T cells in colonic tissue, indicating that alternative dosing regimens might limit toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-022-04685-2

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 99

Metadata

Authors
Eschweiler, S., Ramírez-Suástegui, C., Li, Y., King, E., Chudley, L., Thomas, J., Wood, O., von Witzleben, A., Jeffrey, D., McCann, K., Simon, H., Mondal, M., Wang, A., Dicker, M., Lopez-Guadamillas, E., Chou, T.-F., Dobbs, N. A., Essame, L., Acton, G., Kelly, F., Halbert, G., Sacco, J. J., Schache, A. G., Shaw, R., McCaul, J. A., Paterson, C., Davies, J. H., Brennan, P. A., Singh, R. P., Loadman, P. M., Wilson, W., Hackshaw, A., Seumois, G., Okkenhaug, K., Thomas, G. J., Jones, T. M., Ay, F., Friberg, G., Kronenberg, M., Vanhaesebroeck, B., Vijayanand, P., & Ottensmeier, C. H.
Venue
Nature
Published
2022-05-04
Volume
605
Issue
7911
Pages
741-746
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4229001659
Cited by
99
References
15
FWCI
6.98
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs. https://app.cochat.ai/papers/10.1038/s41586-022-04685-2
The paper
Eschweiler, S., Ramírez-Suástegui, C., Li, Y., King, E., Chudley, L., Thomas, J., Wood, O., von Witzleben, A., Jeffrey, D., McCann, K., Simon, H., Mondal, M., Wang, A., Dicker, M., Lopez-Guadamillas, E., Chou, T.-F., Dobbs, N. A., Essame, L., Acton, G., . . . Ottensmeier, C. H. (2022). Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs. Nature. https://doi.org/10.1038/s41586-022-04685-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.